Menopause cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Menopause}} | {{Menopause}} | ||
{{CMG}} {{RA}} | |||
==Overview== | |||
Given the [[morbidity]] associated with [[menopause]], and the high cost of [[HRT]] and [https://www.health.harvard.edu/menopause/nonhormonal-treatments-for-menopause non- hormonal therapy], current [[pharmacotherapy]] to [[Treatment|treat]] [[menopause]] are [[Cost-effectiveness|cost-effective]]. | |||
==Cost-Effectiveness of Therapy== | |||
*[[Hormone replacement therapy]] is [[Cost-effectiveness|cost-effective]] for the relief of [https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 menopausal symptoms] either was severe or mild. | |||
*[[HRT]] is not [[Cost-effectiveness|cost-effective]] for [[asymptomatic]] women for [[prevention]] of medical diseases associated with [[Menopause|postmenopause]]. | |||
*The [[Cost-effectiveness]] of [[hormone replacement therapy]] ratios between 10,000 - a million $ per QALY (quality-adjusted life expectancy). | |||
*There are several factors that improved [[cost-effectiveness]] such as the long duration of [[therapy]], the presence of [https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 menopausal symptoms], and minimum [[side effects]] of [[Hormone therapy|hormonal therapy]]. | |||
*[https://www.health.harvard.edu/menopause/nonhormonal-treatments-for-menopause Non-hormonal therapy] such as [[SNRIs]] and [[SSRIs]] are relatively [[cost-effectiveness]] for relief of [https://www.mayoclinic.org/diseases-conditions/menopause/symptoms-causes/syc-20353397 menopausal symptoms].<ref name="pmid19857096">{{cite journal| author=Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA| title=Cost-effectiveness of hormone therapy in the United States. | journal=J Womens Health (Larchmt) | year= 2009 | volume= 18 | issue= 10 | pages= 1669-77 | pmid=19857096 | doi=10.1089/jwh.2008.1246 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19857096 }} </ref><ref name="pmid12945798">{{cite journal| author=Burger H| title=Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. | journal=Climacteric | year= 2003 | volume= 6 Suppl 1 | issue= | pages= 11-36 | pmid=12945798 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12945798 }} </ref><ref name="pmid1588862">{{cite journal| author=Cheung AP, Wren BG| title=A cost-effectiveness analysis of hormone replacement therapy in the menopause. | journal=Med J Aust | year= 1992 | volume= 156 | issue= 5 | pages= 312-6 | pmid=1588862 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1588862 }} </ref><ref name="pmid19702449">{{cite journal| author=Williams-Frame A, Carpenter JS| title=Costs of hormonal and nonhormonal prescription medications for hot flashes. | journal=Womens Health (Lond) | year= 2009 | volume= 5 | issue= 5 | pages= 497-502 | pmid=19702449 | doi=10.2217/whe.09.49 | pmc=3637932 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19702449 }} </ref> | |||
<br /> | |||
==References== | ==References== | ||
Latest revision as of 13:58, 2 March 2021
|
Menopause Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Menopause cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Menopause cost-effectiveness of therapy |
|
Risk calculators and risk factors for Menopause cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Rahmah Al-Edresi, M.D.[2]
Overview
Given the morbidity associated with menopause, and the high cost of HRT and non- hormonal therapy, current pharmacotherapy to treat menopause are cost-effective.
Cost-Effectiveness of Therapy
- Hormone replacement therapy is cost-effective for the relief of menopausal symptoms either was severe or mild.
- HRT is not cost-effective for asymptomatic women for prevention of medical diseases associated with postmenopause.
- The Cost-effectiveness of hormone replacement therapy ratios between 10,000 - a million $ per QALY (quality-adjusted life expectancy).
- There are several factors that improved cost-effectiveness such as the long duration of therapy, the presence of menopausal symptoms, and minimum side effects of hormonal therapy.
- Non-hormonal therapy such as SNRIs and SSRIs are relatively cost-effectiveness for relief of menopausal symptoms.[1][2][3][4]
References
- ↑ Lekander I, Borgström F, Ström O, Zethraeus N, Kanis JA (2009). "Cost-effectiveness of hormone therapy in the United States". J Womens Health (Larchmt). 18 (10): 1669–77. doi:10.1089/jwh.2008.1246. PMID 19857096.
- ↑ Burger H (2003). "Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003". Climacteric. 6 Suppl 1: 11–36. PMID 12945798.
- ↑ Cheung AP, Wren BG (1992). "A cost-effectiveness analysis of hormone replacement therapy in the menopause". Med J Aust. 156 (5): 312–6. PMID 1588862.
- ↑ Williams-Frame A, Carpenter JS (2009). "Costs of hormonal and nonhormonal prescription medications for hot flashes". Womens Health (Lond). 5 (5): 497–502. doi:10.2217/whe.09.49. PMC 3637932. PMID 19702449.